Stock AnalizMedpace Holdings, Inc. MEDP
Biotechnology: Commercial Physical & Biological Resarch · IPO 2016 · data as of November 13, 2026
Medpace Holdings, Inc. (MEDP) is a healthcare company listed in the US with a market value of about $18.3B. In the twelve months to September 30, 2026 it had revenue of $2.8B and net income of $518M, a net margin of 18.2%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is track record (5/5); the weakest is value (1/5).
Key numbers: a P/E of 36.3, a price to free cash flow of 27.4, 5-year revenue growth of 22% a year, a 5-year average ROIC of 42%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 32% below the current price.
Score: 3.2 / 5
Checks passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Strong R&D investment or growth above 20%
- Liabilities below 60% of assets
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B | $2.5B | $2.1B | $1.9B | $1.5B | $1.1B | $926M | $861M | $705M | $436M | $422M |
| Net income | $518M | $451M | $404M | $283M | $245M | $182M | $145M | $100M | $73M | $39M | $13M |
| Free cash flow | $668M | $682M | $572M | $397M | $351M | $235M | $227M | $184M | $141M | $86M | $78M |
| EPS (diluted) | $18.01 | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 | $3.84 | $2.67 | $1.97 | $0.98 | $0.37 |
| Net margin | 18.2% | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | 15.7% | 11.7% | 10.4% | 9.0% | 3.2% |
| ROIC | — | 74.7% | 38.9% | 39.2% | 40.7% | 16.3% | 15.4% | 13.1% | 11.6% | 6.1% | 4.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $651.31, 0% below the current price; targets range from $370.00 to $730.00; the consensus rating is “none”; expected EPS is $18.36 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Medpace’s P/E ratio?
About 36.3, based on the last twelve months of diluted earnings per share (forward P/E about 33.6).
Is Medpace stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 32% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Medpace pay a dividend?
Not currently.
Is Medpace a good stock to buy?
We do not give buy or sell advice. Medpace scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.